FedEx Corp has announced the launch of FedEx Life Sciences, a dedicated organisation created to support the increasingly complex movement of pharmaceuticals, medical devices, biologics, clinical trials, and other critical healthcare shipments.
As medicine becomes more specialised, global, and time sensitive, life sciences companies need logistics networks built for precision, visibility, and reliability. From temperature sensitive therapies and clinical trial materials to medical devices and patient critical shipments, healthcare supply chains now require specialized support across highly regulated markets.
FedEx Life Sciences brings together the strength of the company’s global network with a dedicated healthcare team and advanced monitoring capabilities to serve pharmaceutical and healthcare professionals working to deliver care to patients around the world.
As part of the launch, Nick Gennari will exclusively focus on this segment as president of healthcare and life sciences. He joined FedEx in 1992 and has spent much of his more than 30 year tenure driving strategic sales and supply chain solutions for global healthcare, aerospace, and high tech customers, before assuming leadership of the healthcare vertical in 2024. His appointment to lead this newly specialised organization reflects the FedEx commitment to pairing deep, long standing sector expertise with its global logistics and technological capabilities.
‘Transporting vital healthcare deliveries requires more than just standard logistics. It depends upon an intelligent, highly specialised network built for patient critical needs,’ said Brie Carere, executive vice president and chief customer officer, FedEx. ‘Every shipment we move in this space has the potential to support a researcher, a medical professional, or most importantly, a patient waiting for care. To meet these critical demands, FedEx Life Sciences brings together our global network, advanced monitoring, and specialised expertise to make supply chains smarter and more resilient. Under Nick’s leadership, this team will help our customers deliver with the absolute speed, confidence, and precision that patients rely on.’
FedEx Life Sciences builds on significant investments the company has made in healthcare infrastructure and technology. In 2025, the company secured IATA CEIV Pharma Corporate Certification, achieving corporate level certification for ground handling across its air hubs and ramps. In addition, it recently appointed a vice president of global quality, healthcare, and life sciences to oversee global quality management systems for the organisation and support the standards required by pharmaceutical and medical device manufacturers.
FedEx has also expanded its life sciences footprint with a total of six Life Sciences Centres globally. Additionally, a direct flight between Indianapolis and Dublin has strengthened transatlantic connectivity between these two critical pharmaceutical manufacturing hubs, as the company continues to connect global pharmaceutical epicentres.
These assets are supported by FedEx Surround, a monitoring and intervention service that uses machine learning to provide proactive, end to end visibility for critical shipments, identify potential disruptions, and support intervention when timing, temperature, and reliability are essential.
‘Healthcare supply chains are becoming more complex, and the stakes are deeply personal,’ said Nick Gennari, president of healthcare and life sciences. ‘FedEx Life Sciences gives our customers a more focused team, stronger coordination, and specialised expertise to help them move critical healthcare shipments with confidence. Our role is to provide the certainty, visibility, and global reach healthcare innovators need when every shipment matters.’